EpiCept Corporation to Present at the NYSSA Biotech and Specialty Pharmaceuticals Conference
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept Corporation (Nasdaq and OMX Stockholm Exchange: EPCT) today announced that Jack Talley, President and CEO, will be presenting at the New York Society of Security Analysts (NYSSA) Biotech and Specialty Pharmaceuticals Conference on Tuesday, November 30, 2010 at 3:05 p.m. Eastern time in New York City. Mr. Talley will present a company overview.
The presentation will be available live via webcast on November 30, 2010 and for 90 days thereafter. The webcast can be accessed by visiting www.epicept.com.
About EpiCept Corporation
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes EpiCept™ NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.